A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Inclusion Criteria
- CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
- Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
- Diffuse large B-cell lymphoma (DLBCL)
- Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
- DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
- Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
- Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate hematological, renal, hepatic, pulmonary, and cardiac function Key
Exclusion Criteria
- Patients ineligible to receive CD19 CAR T-cell therapy
- Primary CNS lymphoma
- Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
- Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
- Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
- Active autoimmune disease requiring ongoing systemic immunosuppressive therapy. Note: Other protocol defined Inclusion/Exclusion criteria may apply
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07188558.
Locations matching your search criteria
United States
Florida
Tampa
Texas
Houston
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of
rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently
approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell
therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in
patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20
antibody and anthracycline-containing chemotherapy.
Patients will be randomized (1:1) before leukapheresis to receive either:
- Ronde-cel; or
- Investigator's choice of axi-cel or liso-cel
Most patients who receive currently approved CD19-directed CAR T-cell therapies,
including axi-cel and liso-cel, still experience progressive disease, often due to
mechanisms such as CD19 antigen loss or T-cell exhaustion.
Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate
enriched for CD62L-positive naïve and central memory T cells, which are associated with
enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct
that can fully activate upon recognition of either CD19 or CD20, aiming to improve
durability of response despite antigen heterogeneity.
Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be
administered as a single intravenous infusion following fludarabine and cyclophosphamide
lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with
long-term follow-up extending to 15 years.
Trial PhasePhase III
Trial Typetreatment
Lead OrganizationLyell Immunopharma, Inc.
- Primary IDLYL314-102
- Secondary IDsNCI-2026-00303
- ClinicalTrials.gov IDNCT07188558